Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
66 hedge funds and large institutions have $290M invested in Evelo Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 9 closing their positions.
510% more call options, than puts
Call options by funds: $2.54M | Put options by funds: $417K
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
3% more funds holding
Funds holding: 64 → 66 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less capital invested
Capital invested by funds: $332M → $290M (-$41.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.25M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.16M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$1.07M |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
+$873K |
| 5 |
Millennium Management
New York
|
+$755K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$710K |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$309K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$273K |
| 4 |
Two Sigma Advisers
New York
|
-$254K |
| 5 |
Morgan Stanley
New York
|
-$251K |
EVLO Hedge Fund Activity: Q4 2021 in Review
66 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q4 2021, worth a combined $290M — down 13% from $332M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new EVLO positions and 9 closed out — a net gain of 3 holders — while 29 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $2.25M. The largest seller was Vanguard Group, cutting an estimated $710K.
- 66 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q4 2021, up from 64 in Q3 2021.
- Funds reported $290M of Evelo Biosciences, Inc. Common Stock stock for Q4 2021, down 13% quarter-over-quarter.
- 12 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q4 2021 and 9 closed out, a net change of +3 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $2.25M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q4 2021 was Vanguard Group, an estimated $710K sold.
Based on aggregated 13F filings for Q4 2021.